The poster says the FDA confirmed the classification on October 2, 2026, pointing to CourtListener records and arguing the distinction carries real implications.
Recap by typeshit. Post by Facebook on Facebook.
Strive Specialties failed to revive its suit over GLP-1 competition. Novo still faces soft 2026 forecasts and an exploratory CagriSema analysis in women.
Reports say RFK Jr. backs an interim path for specialty compounding, while the FDA lists BPC-157 as a possible safety risk and doctors cite thin human evidence.
Belga reports the number of seized weight loss drugs in Belgium went up again, with officials concerned about an unofficial parallel market.
Clinics took about 60% of supply, and one Seoul clinic got more Mounjaro than 174 hospitals combined. The health ministry warns of sanctions and criminal referrals.
Jonathan and Nir Zontag compared 438,474 diabetes patients on GLP-1 drugs with a matched group. New smell and taste problems were more common but still rare, they report in JAMA.
The HSE drugs group discussed Mounjaro on Tuesday. Today only Saxenda is covered for weight loss, and Lilly has offered a significant price cut.
Loading…